Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
vaccine
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03546361CT.gov CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT00601094CT.gov Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine (this asset) | Jonsson Comprehensive Cancer Center | P1 | CC · 40 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BBB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Docetaxel | SWOG Cancer Research Network | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P1 | CC · 44 |
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-dendritic-cell-adenovirus-ccl21-vaccine-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →